Health CarePharmaceuticals & Biotechnology
  • Price (GBX)2,626
  • Today's Change-15.00 / -0.57%
  • Shares traded17.28k
  • 1 Year change26.25%
  • Beta1.3571
Data delayed at least 15 minutes, as of Jul 27 2016 08:27 BST.
More ▼

Key statistics

Hikma Pharmaceuticals PLC (HIK:LSE) set a new 52-week high during today's trading session when it reached 2,652. Over this period, the share price is up 9.10%.
52-week range
Today
1,575Mar 16 20162,652Jul 27 2016
Markit short selling activity
Low
Med
High
Open2,642
High2,652
Low2,620
Bid2,622
Offer2,625
Previous close2,641
Average volume341.13k
Shares outstanding239.92m
Free float133.46m
P/E (TTM)26.85
Market cap6.15bn GBP
EPS (TTM)0.9545 GBP
Annual div (IAD)21.74 GBX
Annual div yield (IAD)0.85%
Div ex-dateApr 07 2016
Div pay-dateMay 19 2016
Data delayed at least 15 minutes, as of Jul 27 2016 08:27 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Hold at 2,303 on 06 Jun 2016Read the full article

Board of Directors

1/9

Said Darwazah, Chairman and Chief executive officer

2/9

Mazen Darwazah, Executive Vice Chairman, President and CEO of MENA and Emerging Markets

3/9

Ali Al-Husry, Non-executive director

4/9

Robert Pickering, Senior Independent Director

5/9

Michael Ashton, Independent non-executive director

6/9

Breffni Byrne, Independent non-executive director

7/9

Ronald Goode, Independent non-executive director

8/9

Patrick Butler, Independent non-executive director

9/9

Dr. Pamela Kirby, Independent non-executive director

Investor Relations Contact

Susan Ringdal
Investor Relations Director
Email: susan.ringdal@hikma.uk.com
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761

Hikma Pharmaceuticals PLC
13 Hanover Square
London W1S 1HW

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.